⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19143603 | 0.80 | — | — | |
| SCHEMBL1641505 | 0.80 | — | — | |
| SCHEMBL13189779 | 0.78 | — | — | |
| SCHEMBL3401677 | 0.77 | — | — | |
| SCHEMBL27535758 | 0.74 | ALDH1A1 (0.53) | — | |
| SCHEMBL22502065 | 0.74 | KCNH2 (0.40) | — | |
| Acetic Acid SCHEMBL28338607 | 0.73 | NOS2 (0.39) | — | |
| SCHEMBL5904668 | 0.73 | KCNH2 (0.37) | — | |
| SCHEMBL18522479 | 0.73 | KCNH2 (0.37) | — | |
| SCHEMBL23655463 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | claimed |
| EP-3464279-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-11-24 | — | — | EP | claimed |
| EP-3464279-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | claimed |
| WO-2017205464-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-30 | — | — | WO | claimed |
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3464279-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210017164-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20200181126-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-11 | — | — | US | disclosed |
| EP-3464279-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20170342060-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| WO-2017205464-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-30 | — | — | WO | disclosed |